Skip to main content

Market Overview

A Look At How Becton Dickinson Shares Perform After Earnings

Share:
A Look At How Becton Dickinson Shares Perform After Earnings

Medical supplier Becton Dickinson and Co (NYSE: BDX) is scheduled to release fiscal fourth-quarter results Tuesday ahead of the market open.

The Thesis

Becton is likely to wrap the year on a strong note on both the top- and bottom-line, according to JPMorgan Securities analysts.

The research firm sees medical management, urology and surgery as businesses that will remain strong heading into the coming year.

JPMorgan forecast sales of $4.6 billion, $29 million ahead of the consensus. The analyst expects top-line growth to be predominantly driven by the interventional business.

Gross margin is expected to come in slightly lower than the expected 57.3%, and this figure is likely to be offset by a lower tax rate and a stronger top-line, the analyst said.

JPMorgan forecast earnings per share of $3.30.

2020 Guidance: What To Expect

On the earnings call, the focus is likely to be on fiscal year 2020 guidance, according to JPMorgan. 

The research firm expects the company to guide to 5-6% organic sales and EPS of $12.85-$13.05 for the year.

The firm sees top-line upside coming from a ramp in Bard synergies and strength across the various businesses, particularly with Pumps, Pyxis and new software introductions driving the Medication Management System; easier comps; and growth of core business in Europe for Diagnostics and new product launches in Peripheral Intervention.

Looking at the historical trend since 2008, the firm noted that Becton reported top-line beats 61% of the time and bottom-line beats 85% of the time. The company's average EPS beat is about 6 cents, according to JPMorgan. 

Notwithstanding this, Becton stock reacted negatively 61% of the time, with an average decline of 0.5%, the research firm said. 

Price Action

Becton shares were trading higher by 1.16% at $261.14 at the time of publication. 

Related Links:

The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Latest Ratings for BDX

DateFirmActionFromTo
Feb 2022Morgan StanleyMaintainsOverweight
Feb 2022SVB LeerinkMaintainsMarket Perform
Jan 2022Morgan StanleyMaintainsOverweight

View More Analyst Ratings for BDX

View the Latest Analyst Ratings

 

Related Articles (BDX)

View Comments and Join the Discussion!

Posted-In: JPMorgan Securities medical suppliesAnalyst Color Health Care Previews Analyst Ratings Trading Ideas General

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com